To Whom It May Concern

Oct. 4, 2018

NanoCarrier Co. Ltd.
Ichiro Nakatomi, President & CEO
(Code No. 4571 TSE Mothers)

NC-6004 Phase II study IND in combination with immunecheck point inhibitor of Keytruda®

NanoCarrier has prepared study protocol of NC-6004 phase II study in combination with Keytruda® (Pembrolizumab, anti-PD-1 monoclonal antibody) for head and neck cancer. On October 01 US time, 2018, NanoCarrier submitted the study protocol as IND to the US FDA (Food and Drug Administration).

[Outline of the Phase II clinical study]

Target indication:	Head and Neck Caner
Conducted region:	US (expand sequentially)
Study objective:	Phase IIa part
	Safety assessment of NC-6004 in combination with Keytruda®
	Determination of NC-6004 recommended dose in combination with Keytruda®
	Phase IIb part
	Efficacy assessment in combination with Keytruda®
Study duration:	Approximately 3 years from study initiation (planned)

This study expands combination therapy potency of NC-6004 in combination with immunecheck point inhibitor. NanoCarrier is preparing the study protocol submission in European countries as well as Asian countries sequentially followed by US FDA submission. In worldwide, approximately 30 study sites will participate into the study.

Please note that this case will have no impact on the business results for the fiscal year ending March 2019.

*Immune checkpoint inhibitors

Tasuku Honjo, distinguished professor at Kyoto University, has won the 2018 Nobel Prize in physiology and medicine. Professor Honjo has discovered a protein named PD-1 which brakes immune activity. Immunecheck point inhibitor, which shows anti-cancer activity by removing such immune suppression by PD-1 pathway, has been spotlighted as novel immune-oncology therapy and has been developed actively in worldwide.

In Japan, four such drugs have been approved, namely, Nivolumab (product name: Opdivo®), Pembrolizumab (product name: Keytruda®), Atezolizumab (product name: Tecentriq®), Avelumab (product name: Bavencio®) and Durvalumab (product name: Imfinzi®).

Contact: Tetsuhito Matsuyama
Director, CFO and Head of CEO's Office
Phone: 03-3241-0553